Literature DB >> 14714214

Ginsenosides Rb1 and Rg1 effects on survival and neurite growth of MPP+-affected mesencephalic dopaminergic cells.

K Radad1, G Gille, R Moldzio, H Saito, K Ishige, W-D Rausch.   

Abstract

Ginsenosides Rb1 and Rg1 are the main active ingredients of Panax ginseng C.A. Meyer (Araliaceae). They appear to exert protection against ischaemia and anoxic damage in animal models, suggesting an antioxidative and cytoprotective role. In our study, primary cultures from embryonic mouse mesencephalon are applied to examine the effects of these two ginsenosides on neuritic growth of dopaminergic cells and their survival affected by 1-methyl-4-phenylpyridinium-iodide (MPP(+)). Ginsenoside Rb1 (at 10 microM) enhanced the survival of dopaminergic neurons by 19% compared to untreated control. MPP(+) (at 1 microM) significantly reduced the number of dopaminergic neurons and severely affected neuronal processes. Both ginsenosides counteracted these degenerations and significantly protected lengths and numbers of neurites of TH(+) cells. Both compounds however could not prevent the cell loss caused by MPP(+). Our study thus indicates partial neurotrophic and neuroprotective actions of ginsenosides Rb1 and Rg1 in dopaminergic cell culture.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14714214     DOI: 10.1007/s00702-003-0063-1

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  25 in total

1.  Swainsonine as a lysosomal toxin affects dopaminergic neurons.

Authors:  Qinfan Li; Yingzi Wang; Rudolf Moldzio; Weimin Lin; Wolf-Dieter Rausch
Journal:  J Neural Transm (Vienna)       Date:  2012-06-24       Impact factor: 3.575

Review 2.  Potential neuroprotective activity of Ginseng in Parkinson's disease: a review.

Authors:  Elena González-Burgos; Carlos Fernandez-Moriano; M Pilar Gómez-Serranillos
Journal:  J Neuroimmune Pharmacol       Date:  2014-10-29       Impact factor: 4.147

Review 3.  Ginsenosides from American ginseng: chemical and pharmacological diversity.

Authors:  Lian-Wen Qi; Chong-Zhi Wang; Chun-Su Yuan
Journal:  Phytochemistry       Date:  2011-03-09       Impact factor: 4.072

4.  Ginsenoside Rg1 protects dopaminergic neurons in a rat model of Parkinson's disease through the IGF-I receptor signalling pathway.

Authors:  Li Xu; Wen-Fang Chen; Man-Sau Wong
Journal:  Br J Pharmacol       Date:  2009-08-24       Impact factor: 8.739

5.  Glutamate-induced cell death and formation of radicals can be reduced by lisuride in mesencephalic primary cell culture.

Authors:  R Moldzio; K Radad; J C Duvigneau; B Kranner; C Krewenka; C Piskernik; W D Rausch
Journal:  J Neural Transm (Vienna)       Date:  2006-02-06       Impact factor: 3.575

6.  Ginsenoside Rd and ginsenoside Re offer neuroprotection in a novel model of Parkinson's disease.

Authors:  Xinmu Zhang; Yingzi Wang; Cheng Ma; Yan Yan; Yang Yang; Xin Wang; Wolf-Dieter Rausch
Journal:  Am J Neurodegener Dis       Date:  2016-03-01

7.  Neuroprotective effects of ginsenosides Rh1 and Rg2 on neuronal cells.

Authors:  Xiao-Fan Li; Cathy Nga-Ping Lui; Zhi-Hong Jiang; Yung Kin-Lam Ken
Journal:  Chin Med       Date:  2011-05-19       Impact factor: 5.455

8.  Neuroprotective Effect and Antioxidant Potency of Fermented Cultured Wild Ginseng Root Extracts of Panax ginseng C.A. Meyer in Mice.

Authors:  Chul-Joong Kim; Hyeon-Yeol Ryu; Somin Lee; Han-Joo Lee; Yoon-Soek Chun; Jong-Kyu Kim; Chang-Yeon Yu; Bimal Kumar Ghimire; Jae-Geun Lee
Journal:  Molecules       Date:  2021-05-18       Impact factor: 4.411

9.  A comprehensive review of the therapeutic and pharmacological effects of ginseng and ginsenosides in central nervous system.

Authors:  Hee Jin Kim; Pitna Kim; Chan Young Shin
Journal:  J Ginseng Res       Date:  2013-03       Impact factor: 6.060

10.  Ganoderma lucidum Protects Dopaminergic Neuron Degeneration through Inhibition of Microglial Activation.

Authors:  Ruiping Zhang; Shengli Xu; Yanning Cai; Ming Zhou; Xiaohong Zuo; Piu Chan
Journal:  Evid Based Complement Alternat Med       Date:  2011-06-18       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.